Syndax Pharmaceuticals Inc
NASDAQ:SNDX

Watchlist Manager
Syndax Pharmaceuticals Inc Logo
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
Watchlist
Price: 11.45 USD 2.6% Market Closed
Market Cap: 985.3m USD

Wall Street
Price Targets

SNDX Price Targets Summary
Syndax Pharmaceuticals Inc

Wall Street analysts forecast SNDX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SNDX is 35.98 USD with a low forecast of 17.17 USD and a high forecast of 53.55 USD.

Lowest
Price Target
17.17 USD
50% Upside
Average
Price Target
35.98 USD
214% Upside
Highest
Price Target
53.55 USD
368% Upside
Syndax Pharmaceuticals Inc Competitors:
Price Targets
GRAL
Grail Inc
16% Downside
MDXG
MiMedx Group Inc
89% Upside
HPHA
Heidelberg Pharma AG
171% Upside
PRME
Prime Medicine Inc
344% Upside
IMMX
Immix Biopharma Inc
201% Upside

Revenue
Forecast

Revenue Estimate
Syndax Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Syndax Pharmaceuticals Inc's revenue is 45%. The projected CAGR for the next 3 years is 150%.

45%
Past Growth
150%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Syndax Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss

Net Income
Forecast

Net Income Estimate
Syndax Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-59%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SNDX's stock price target?
Price Target
35.98 USD

According to Wall Street analysts, the average 1-year price target for SNDX is 35.98 USD with a low forecast of 17.17 USD and a high forecast of 53.55 USD.

What is Syndax Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
150%

For the last 8 years the compound annual growth rate for Syndax Pharmaceuticals Inc's revenue is 45%. The projected CAGR for the next 3 years is 150%.

Back to Top